FOLH1 and prostate cancer: Indeed, IRDye700DX-PSMA: (i) is highly specific in targeting prostate cancer cells demonstrating an uptake correlated with PSMA expression level (Figure 2 and Figure 3), (ii) allows NIR imaging with nanomolar dose up to 24 h post administration and, at the same time, shows a rapid clearance from PSMA-negative tissue (bladder included), (iii) may help surgeons to visualize negative tumour margins, iv) showed concentration dependent phototoxicity in PSMA+ cells but not in PSMA-, and v) delays tumour progression in photodynamic treated mice.